Trial Profile
Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs BMS 599626 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 24 Aug 2005 New trial record.